Physician profile
Michael E Goltzman
NPI 1326570722
$9,616.64
in general payments reported to CMS, 2019-2025
42 companies · $2,978 in 2025
The $2,978 reported for 2025 was more than what 86% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,377 · 2023: $1,886 · 2024: $3,376 · 2025: $2,978.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,793 · Consulting Fee: $1,500 · Travel and Lodging: $907 · Education: $39.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,792.68 |
| Consulting Fee | $1,500.00 |
| Travel and Lodging | $907.12 |
| Education | $39.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,577.05 | 2024-2025 | Rezum Generator, Lithovue |
| Histosonics, INC. | $1,164.31 | 2025 | |
| Janssen Biotech, INC. | $778.26 | 2022-2025 | Erleada, Akeega, Balversa |
| Sumitomo Pharma America, INC. | $712.61 | 2023-2025 | Orgovyx, Gemtesa |
| Coloplast Corp | $706.96 | 2022-2025 | |
| Teleflex LLC | $638.84 | 2022-2025 | Urolift, Barrigel |
| Bayer Healthcare Pharmaceuticals INC. | $516.03 | 2022-2025 | |
| Pfizer INC. | $376.44 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $348.73 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Progenics Pharmaceuticals, INC. | $269.10 | 2022-2025 | Pylarify |
| Astellas Pharma US INC | $226.22 | 2022-2025 | Xtandi, Veozah, Myrbetriq |
| Axonics, INC. | $223.56 | 2023-2024 | Axonics |
| Accord Healthcare, INC. | $223.47 | 2022-2025 | |
| Procept Biorobotics Corporation | $212.40 | 2024 | Aquabeam System |
| Urogen Pharma, INC. | $199.36 | 2022-2025 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $168.83 | 2024-2025 | Adstiladrin |
| Endo USA, INC. | $148.01 | 2025 | Aveed, Xiaflex, Edex |
| Innovation Technologies INC | $114.23 | 2023 | Irrisept |
| Abbvie INC. | $114.14 | 2022-2025 | |
| Agiliti Surgical, INC. | $102.89 | 2023-2024 | Soltive, Trinity, Sonablate |
| Urovant Sciences INC | $98.15 | 2022 | |
| Myriad Genetic Laboratories, INC. | $85.39 | 2023 | Myrisk, Prolaris |
| Novartis Pharmaceuticals Corporation | $84.54 | 2025 | |
| Tolmar, INC. | $68.38 | 2023-2025 | Jatenzo |
| Myovant Sciences INC. | $50.82 | 2022 | |
| Sun Pharmaceutical Industries INC. | $50.72 | 2023 | Yonsa |
| Endo Pharmaceuticals INC. | $35.18 | 2023 | Aveed, Xiaflex |
| Tolmar Pharmaceuticals, INC. | $35.15 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $31.03 | 2025 | |
| Telix Pharmaceuticals | $25.70 | 2023 | Illuccix |
| Conmed Corporation | $24.64 | 2024 | Airseal |
| Mission Pharmacal Company | $22.60 | 2022 | |
| Photocure INC | $21.39 | 2024 | Cysview |
| Medtronic, INC. | $20.29 | 2023 | Interstim |
| Becton, Dickinson and Company | $20.11 | 2024 | Bard Urinary Drainage Bag |
| Olympus America INC. | $19.85 | 2025 | Itind System |
| Laborie Medical Technologies Corp. | $19.04 | 2024 | Optilume Bph Drug Coated Balloon Catheter |
| Palette Life Sciences, INC. | $18.48 | 2023 | |
| Calyxo, INC. | $16.61 | 2025 | Cvac Aspiration System |
| Immunitybio, INC. | $16.20 | 2024 | |
| Profound Medical Corp. | $16.10 | 2025 | Tulsa-Pro |
| Angiodynamics, INC. | $14.83 | 2024 | Nanoknife |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Goltzman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.